Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 5.87
NRCIB's Cash to Debt is ranked higher than
59% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.88 vs. NRCIB: 5.87 )
Ranked among companies with meaningful Cash to Debt only.
NRCIB' s Cash to Debt Range Over the Past 10 Years
Min: 0.05  Med: 2.08 Max: No Debt
Current: 5.87
Equity to Asset 0.68
NRCIB's Equity to Asset is ranked higher than
64% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. NRCIB: 0.68 )
Ranked among companies with meaningful Equity to Asset only.
NRCIB' s Equity to Asset Range Over the Past 10 Years
Min: 0.51  Med: 0.67 Max: 0.81
Current: 0.68
0.51
0.81
Interest Coverage 132.48
NRCIB's Interest Coverage is ranked higher than
53% of the 128 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 83.10 vs. NRCIB: 132.48 )
Ranked among companies with meaningful Interest Coverage only.
NRCIB' s Interest Coverage Range Over the Past 10 Years
Min: 19.16  Med: 37.91 Max: 132.48
Current: 132.48
19.16
132.48
F-Score: 6
Z-Score: 10.23
M-Score: -2.60
WACC vs ROIC
0.53%
36.38%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 27.73
NRCIB's Operating margin (%) is ranked higher than
93% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.53 vs. NRCIB: 27.73 )
Ranked among companies with meaningful Operating margin (%) only.
NRCIB' s Operating margin (%) Range Over the Past 10 Years
Min: 21.86  Med: 24.24 Max: 28.63
Current: 27.73
21.86
28.63
Net-margin (%) 18.75
NRCIB's Net-margin (%) is ranked higher than
92% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.59 vs. NRCIB: 18.75 )
Ranked among companies with meaningful Net-margin (%) only.
NRCIB' s Net-margin (%) Range Over the Past 10 Years
Min: 13.41  Med: 14.99 Max: 18.75
Current: 18.75
13.41
18.75
ROE (%) 24.14
NRCIB's ROE (%) is ranked higher than
94% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.49 vs. NRCIB: 24.14 )
Ranked among companies with meaningful ROE (%) only.
NRCIB' s ROE (%) Range Over the Past 10 Years
Min: 16.97  Med: 21.04 Max: 26.84
Current: 24.14
16.97
26.84
ROA (%) 15.85
NRCIB's ROA (%) is ranked higher than
96% of the 213 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.30 vs. NRCIB: 15.85 )
Ranked among companies with meaningful ROA (%) only.
NRCIB' s ROA (%) Range Over the Past 10 Years
Min: 10.1  Med: 11.76 Max: 15.85
Current: 15.85
10.1
15.85
ROC (Joel Greenblatt) (%) 265.33
NRCIB's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -11.24 vs. NRCIB: 265.33 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NRCIB' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 84.92  Med: 115.85 Max: 265.33
Current: 265.33
84.92
265.33
Revenue Growth (3Y)(%) 5.50
NRCIB's Revenue Growth (3Y)(%) is ranked higher than
57% of the 141 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.80 vs. NRCIB: 5.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NRCIB' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -11.2  Med: 10.3 Max: 19.8
Current: 5.5
-11.2
19.8
EBITDA Growth (3Y)(%) 4.60
NRCIB's EBITDA Growth (3Y)(%) is ranked higher than
61% of the 123 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. NRCIB: 4.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NRCIB' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -14.2  Med: 10.6 Max: 44.1
Current: 4.6
-14.2
44.1
EPS Growth (3Y)(%) 4.70
NRCIB's EPS Growth (3Y)(%) is ranked higher than
62% of the 117 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.20 vs. NRCIB: 4.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NRCIB' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -17.2  Med: 12.3 Max: 58.7
Current: 4.7
-17.2
58.7
» NRCIB's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-10)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2014

NRCIB Guru Trades in Q2 2014

Chuck Royce 2,100 sh (unchged)
» More
Q3 2014

NRCIB Guru Trades in Q3 2014

Chuck Royce 2,100 sh (unchged)
» More
Q4 2014

NRCIB Guru Trades in Q4 2014

Chuck Royce 1,780 sh (-15.24%)
» More
Q1 2015

NRCIB Guru Trades in Q1 2015

Chuck Royce Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NRCIB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:NAS:BEAT, NAS:SRDX, OTCPK:BMLIF, NAS:HSKA, NAS:NTRA, AMEX:SENS, NAS:ONVO, NAS:RDNT, NYSE:ARA, OTCPK:EDTXF, NAS:TRIB, NAS:NEO, NYSE:NVTA, NAS:OXFD, NAS:LNTH, NAS:FLDM, NYSE:ENZ, NAS:NVDQ, NAS:QTNT, NAS:TTOO » details
National Research Corp implements surveys and performs analysis. Its subscription-based solutions provide actionable information and analysis to healthcare organizations.

National Research Corp is a Wisconsin corporation, founded in 1981. The Company implements surveys and performs analysis that recognize a provider's strengths and problem areas, and then uses the data to design specific, measurable improvement strategies. The Company's portfolio of subscription-based solutions provide actionable information and analysis to healthcare organizations and payers across a range of mission-critical, constituent-related elements, including patient experience and satisfaction, community population health risks, workforce engagement, community perceptions, and physician engagement. The Company partners with clients across the continuum of healthcare services. The Company's clients range from acute care hospitals and post-acute providers, such as home health, long term care and hospice, to numerous payer organizations. The two segments, organized by geographic area, are National Research Corporation (United States) and National Research Corporation Canada, which each offer a portfolio of solutions to address specific market needs around growth, retention, engagement and thought leadership for healthcare organizations. The Company's primary competitors among such specialty firms include Press Ganey. The Company competes with traditional market research firms which are significant providers of survey-based, general market research and firms which provide services or products that complement healthcare performance assessments such as healthcare software or information systems.

Top Ranked Articles about National Research Corp

Backtesting Feature Identifies Top-Performing Strategies New feature insight: high dividend yields offer strong portfolio returns
GuruFocus launched the new Backtesting feature within the All-in-One Guru Screener on June 20, allowing users to model an investing strategy’s performance relative to the Standard & Poor’s 500 index, one of the most commonly used benchmarks. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 12.51
NRCIB's P/E(ttm) is ranked lower than
70% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.07 vs. NRCIB: 12.51 )
Ranked among companies with meaningful P/E(ttm) only.
NRCIB' s P/E(ttm) Range Over the Past 10 Years
Min: 2.19  Med: 4.12 Max: 19.56
Current: 12.51
2.19
19.56
Forward P/E 37.59
NRCIB's Forward P/E is ranked lower than
81% of the 42 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.83 vs. NRCIB: 37.59 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 12.51
NRCIB's PE(NRI) is ranked lower than
70% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.43 vs. NRCIB: 12.51 )
Ranked among companies with meaningful PE(NRI) only.
NRCIB' s PE(NRI) Range Over the Past 10 Years
Min: 2.19  Med: 4.12 Max: 19.56
Current: 12.51
2.19
19.56
Price/Owner Earnings (ttm) 12.08
NRCIB's Price/Owner Earnings (ttm) is ranked lower than
67% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.41 vs. NRCIB: 12.08 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
NRCIB' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 1.42  Med: 4.24 Max: 23.78
Current: 12.08
1.42
23.78
P/B 10.75
NRCIB's P/B is ranked lower than
91% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.41 vs. NRCIB: 10.75 )
Ranked among companies with meaningful P/B only.
NRCIB' s P/B Range Over the Past 10 Years
Min: 0.42  Med: 0.68 Max: 16.24
Current: 10.75
0.42
16.24
P/S 2.33
NRCIB's P/S is ranked lower than
76% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.27 vs. NRCIB: 2.33 )
Ranked among companies with meaningful P/S only.
NRCIB' s P/S Range Over the Past 10 Years
Min: 0.32  Med: 0.59 Max: 3.3
Current: 2.33
0.32
3.3
PFCF 12.09
NRCIB's PFCF is ranked lower than
74% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.85 vs. NRCIB: 12.09 )
Ranked among companies with meaningful PFCF only.
NRCIB' s PFCF Range Over the Past 10 Years
Min: 1.44  Med: 3.59 Max: 19.4
Current: 12.09
1.44
19.4
POCF 10.31
NRCIB's POCF is ranked lower than
85% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.84 vs. NRCIB: 10.31 )
Ranked among companies with meaningful POCF only.
NRCIB' s POCF Range Over the Past 10 Years
Min: 1.23  Med: 2.97 Max: 17.12
Current: 10.31
1.23
17.12
EV-to-EBIT 14.35
NRCIB's EV-to-EBIT is ranked higher than
70% of the 94 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.92 vs. NRCIB: 14.35 )
Ranked among companies with meaningful EV-to-EBIT only.
NRCIB' s EV-to-EBIT Range Over the Past 10 Years
Min: 0.8  Med: 3.2 Max: 17.8
Current: 14.35
0.8
17.8
EV-to-EBITDA 12.64
NRCIB's EV-to-EBITDA is ranked higher than
59% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 16.14 vs. NRCIB: 12.64 )
Ranked among companies with meaningful EV-to-EBITDA only.
NRCIB' s EV-to-EBITDA Range Over the Past 10 Years
Min: 0.7  Med: 2.4 Max: 14.3
Current: 12.64
0.7
14.3
Shiller P/E 14.31
NRCIB's Shiller P/E is ranked higher than
86% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 41.82 vs. NRCIB: 14.31 )
Ranked among companies with meaningful Shiller P/E only.
NRCIB' s Shiller P/E Range Over the Past 10 Years
Min: 3.47  Med: 6.81 Max: 19.83
Current: 14.31
3.47
19.83
Current Ratio 1.46
NRCIB's Current Ratio is ranked lower than
78% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.48 vs. NRCIB: 1.46 )
Ranked among companies with meaningful Current Ratio only.
NRCIB' s Current Ratio Range Over the Past 10 Years
Min: 0.49  Med: 1.69 Max: 5.41
Current: 1.46
0.49
5.41
Quick Ratio 1.46
NRCIB's Quick Ratio is ranked lower than
71% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. NRCIB: 1.46 )
Ranked among companies with meaningful Quick Ratio only.
NRCIB' s Quick Ratio Range Over the Past 10 Years
Min: 0.49  Med: 1.69 Max: 5.41
Current: 1.46
0.49
5.41
Days Sales Outstanding 38.28
NRCIB's Days Sales Outstanding is ranked higher than
81% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 64.52 vs. NRCIB: 38.28 )
Ranked among companies with meaningful Days Sales Outstanding only.
NRCIB' s Days Sales Outstanding Range Over the Past 10 Years
Min: 29.97  Med: 48.96 Max: 75.1
Current: 38.28
29.97
75.1
Days Payable 5.98
NRCIB's Days Payable is ranked lower than
95% of the 150 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.15 vs. NRCIB: 5.98 )
Ranked among companies with meaningful Days Payable only.
NRCIB' s Days Payable Range Over the Past 10 Years
Min: 3  Med: 9.51 Max: 184.63
Current: 5.98
3
184.63

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 5.14
NRCIB's Dividend Yield is ranked higher than
94% of the 81 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.18 vs. NRCIB: 5.14 )
Ranked among companies with meaningful Dividend Yield only.
NRCIB' s Dividend Yield Range Over the Past 10 Years
Min: 0.94  Med: 12.89 Max: 23.19
Current: 5.14
0.94
23.19
Dividend Payout 0.64
NRCIB's Dividend Payout is ranked lower than
69% of the 54 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.30 vs. NRCIB: 0.64 )
Ranked among companies with meaningful Dividend Payout only.
NRCIB' s Dividend Payout Range Over the Past 10 Years
Min: 0.28  Med: 0.59 Max: 3.25
Current: 0.64
0.28
3.25
Dividend Growth (3y) -9.10
NRCIB's Dividend Growth (3y) is ranked lower than
84% of the 31 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. NRCIB: -9.10 )
Ranked among companies with meaningful Dividend Growth (3y) only.
NRCIB' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 20.5
Current: -9.1
0
20.5
Forward Dividend Yield 5.48
NRCIB's Forward Dividend Yield is ranked higher than
92% of the 75 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.14 vs. NRCIB: 5.48 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 2.23
NRCIB's Yield on cost (5-Year) is ranked higher than
65% of the 96 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. NRCIB: 2.23 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
NRCIB' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.41  Med: 5.54 Max: 10.05
Current: 2.23
0.41
10.05
3-Year Average Share Buyback Ratio -92.00
NRCIB's 3-Year Average Share Buyback Ratio is ranked lower than
93% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.80 vs. NRCIB: -92.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NRCIB' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -93.8  Med: -0.1 Max: 1.9
Current: -92
-93.8
1.9

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 145.91
NRCIB's Price/Net Current Asset Value is ranked lower than
98% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.62 vs. NRCIB: 145.91 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
NRCIB' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.33  Med: 1.7 Max: 716.4
Current: 145.91
0.33
716.4
Price/Tangible Book 46.76
NRCIB's Price/Tangible Book is ranked lower than
99% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. NRCIB: 46.76 )
Ranked among companies with meaningful Price/Tangible Book only.
NRCIB' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.21  Med: 0.75 Max: 2687.69
Current: 46.76
0.21
2687.69
Price/Projected FCF 1.07
NRCIB's Price/Projected FCF is ranked lower than
71% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.04 vs. NRCIB: 1.07 )
Ranked among companies with meaningful Price/Projected FCF only.
NRCIB' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.12  Med: 0.3 Max: 2.17
Current: 1.07
0.12
2.17
Price/Median PS Value 3.96
NRCIB's Price/Median PS Value is ranked lower than
98% of the 166 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.02 vs. NRCIB: 3.96 )
Ranked among companies with meaningful Price/Median PS Value only.
NRCIB' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.25  Med: 0.89 Max: 5.59
Current: 3.96
0.25
5.59
Price/Graham Number 5.10
NRCIB's Price/Graham Number is ranked lower than
97% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.35 vs. NRCIB: 5.10 )
Ranked among companies with meaningful Price/Graham Number only.
NRCIB' s Price/Graham Number Range Over the Past 10 Years
Min: 0.12  Med: 0.37 Max: 43.68
Current: 5.1
0.12
43.68
Earnings Yield (Greenblatt) (%) 7.00
NRCIB's Earnings Yield (Greenblatt) (%) is ranked higher than
86% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.20 vs. NRCIB: 7.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NRCIB' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 5.6  Med: 31.65 Max: 118.8
Current: 7
5.6
118.8
Forward Rate of Return (Yacktman) (%) 3.57
NRCIB's Forward Rate of Return (Yacktman) (%) is ranked lower than
93% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.44 vs. NRCIB: 3.57 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
NRCIB' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 0.5  Med: 37.1 Max: 65
Current: 3.57
0.5
65

More Statistics

Revenue (TTM) (Mil) $105.6
EPS (TTM) $ 2.80
Beta-0.15
Short Percentage of Float1.30%
52-Week Range $31.36 - 44.60
Shares Outstanding (Mil)24.44

Analyst Estimate

Dec16 Dec17
Revenue (Mil $) 110 120
EPS ($) 0.83 0.93
EPS w/o NRI ($) 0.83 0.93
EPS Growth Rate
(3Y to 5Y Estimate)
13.00%
Dividends Per Share ($)
» More Articles for NRCIB

Headlines

Articles On GuruFocus.com
Backtesting Feature Identifies Top-Performing Strategies Aug 31 2016 
Meridian Funds Comments on National Research Corp Jun 20 2014 
My 4 Favorite Stocks From The Undervalued Predictable Screener Oct 11 2013 
Four Predictable, Undervalued Stocks Held by Billionaire Investors Sep 22 2013 
13 Not Expensive Stocks with Dividend Yields Over 3% as Well as a Consistent Business Sep 10 2013 
4 Really Undervalued Stocks With High Quality Dividends And A Consistent Business Sep 02 2013 

More From Other Websites
Verisk Seeks to Grow with Enhanced Insurance Portfolio Sep 21 2016
Verisk (VRSK) Bets on Growth with Insurance Unit Launch Sep 20 2016
National Research Corp.: Strong price momentum but will it sustain? Sep 19 2016
ETF’s with exposure to National Research Corp. : September 13, 2016 Sep 13 2016
National Research Corporation Introduces Enhanced Market Insights Solution Sep 09 2016
Verisk Focuses on Organic Growth with Product Advancement Sep 08 2016
National Research Corporation Declares Quarterly Dividend Aug 30 2016
National Research Corporation Recognizes Award Winners at Patient-Centered Care Symposium in San... Aug 30 2016
Sentara Medical Group and National Research Corporation Take Podium at SHSMD Aug 24 2016
TransUnion Appoints Henry Chao as Advisory Board Member Aug 18 2016
Verisk's Unit Unveils MSDgen for GHS & REACH Compliance Aug 17 2016
ETF’s with exposure to National Research Corp. : August 16, 2016 Aug 16 2016
Rhode Island Nursing Homes Use Resident Insights to Keep Care Elevated Above National Benchmarks Aug 11 2016
National Research Corp. :NRCIB-US: Earnings Analysis: Q2, 2016 By the Numbers : August 4, 2016 Aug 04 2016
Tenth Annual National Research Excellence Award Recognizes Long Term Care and Senior Living... Aug 03 2016
National Research posts 2Q profit Aug 02 2016
National Research posts 2Q profit Aug 02 2016
National Research Corporation Announces Second Quarter 2016 Results Aug 02 2016
National Research Corporation to Broadcast Its 2016 Second Quarter Conference Call Live on the... Jul 20 2016
National Research Corporation Declares Quarterly Dividend May 12 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)